Research map: Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma

Back to the article

Papers in this map

  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification · Bruce D. Cheson · 2014 · 5729 citations · Cited by this paper
  2. Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation · 2026 · Related
  3. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · Daniel W. Lee · 2018 · 3668 citations · Cited by this paper
  4. Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer · 2026 · Related
  5. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma · Thomas Elmer Witzig · 2002 · 1172 citations · Cited by this paper
  6. Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation · 2026 · Related
  7. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review · Bertrand Coiffier · 2008 · 798 citations · Cited by this paper
  8. Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations · 2026 · Related
  9. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial · Caron Alyce Jacobson · 2021 · 664 citations · Cited by this paper
  10. A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics · 2026 · Related
  11. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial · Franck Morschhauser · 2020 · 608 citations · Cited by this paper
  12. Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva · 2026 · Related
  13. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial · Catherine Thiéblemont · 2022 · 578 citations · Cited by this paper
  14. Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing · 2026 · Related
  15. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma · John Paul Leonard · 2019 · 433 citations · Cited by this paper
  16. Impacts of Uremic Toxins on the Population Pharmacokinetics of Total Mycophenolic Acid and its Glucuronide Metabolite in Adult Kidney Transplant Recipients · 2026 · Related
  17. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial · Laurie Helen Sehn · 2016 · 349 citations · Cited by this paper
  18. Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty · 2026 · Related
  19. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma · John G. Gribben · 2015 · 297 citations · Cited by this paper
  20. ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma · 2026 · Related
  21. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study · Martin H. Dreyling · 2019 · 173 citations · Cited by this paper
  22. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study · Kim Linton · 2024 · 166 citations · Cited by this paper
  23. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial · Catherine Thiéblemont · 2024 · 143 citations · Cited by this paper
  24. Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype association · Baruch D. Jakubovic · 2020 · 44 citations · Cited by this paper
  25. A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL) · Gilles Salles · 2022 · 31 citations · Cited by this paper
  26. Interleukin-6 and cytokine release syndrome · Erika Yue Lee · 2022 · 30 citations · Cited by this paper
  27. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma · Koji Izutsu · 2023 · 30 citations · Cited by this paper
  28. Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma · Tommy Ruosi Li · 2024 · 12 citations · Cited by this paper
  29. EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL. · Julie Marie Vose · 2024 · 10 citations · Cited by this paper
  30. Abstract 2798: Simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling · Tommy Ruosi Li · 2023 · 8 citations · Cited by this paper
  31. Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma · Tommy Ruosi Li · 2025 · 8 citations · Cited by this paper
  32. An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date · Umut Yılmaz · 2021 · 6 citations · Cited by this paper
  33. Safety in Subsequent Lines of Therapy in Patients With Relapsed Refractory Follicular Lymphoma · Tajuana Bradley · 2024 · 1 citation · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper

Source: OpenAlex (CC0)